Stay updated with breaking news from Absci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Casdin Capital LLC cut its holdings in shares of Absci Co. (NASDAQ:ABSI – Free Report) by 74.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,368,260 shares of the company’s stock after selling 4,025,000 shares during the period. Casdin Capital […]
Absci Co. (NASDAQ:ABSI – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 2,300,000 shares, a decline of 6.5% from the October 31st total of 2,460,000 shares. Based on an average daily volume of 323,400 shares, the […]
AstraZeneca taps into AI firms to build cancer antibodies to replace chemotherapy. . Generative AI-Built Cancer Antibodies will reportedly be worked on by AstraZeneca and Absci after signing a deal approximately worth $247 million, as reported by Reuters.
Absci (ABSI) announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target.
The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.